CEO Message

In 1995 when I started Asymchem with a single laboratory in North Carolina’s Research Triangle Park (RTP), I did it with not much more than my unbridled enthusiasm for chemistry. Fortunately this period of steadfast faith in therapeutics coincided with the budding Chinese CDMO industry. In 1998, through careful consideration and investment, Asymchem extended its fast-growing operations to China and the story began to unfold.

Today Asymchem employs more than 5000 people at eight sites and count as our clients as the world’s top pharmaceutical companies. While I’m proud of such a significant accomplishment, our numerous advances in novel technology including the commercial-sized application of flow chemistry in API manufacturing, have fueled my continued passion for chemistry. Along with the recent construction of Asymchem’s multidimensional service platform, we’ve realized that our enriched expertise and commitment to innovation can extend beyond “big pharma” to those newly emerged biotech labs and even smaller sized specialty pharmaceutical companies adopting cutting-edge therapeutics. Using the “Know How” spirit, Asymchem has made it our mission to help these innovators successfully bring their products to market.

Dr. Hao Hong
CEO, Chairman

Senior Management

James Gage, Ph.D.

Chief Science Officer

Rui Yang

Chief Operating Officer

Da Zhang

Chief Financial Officer

Elut Hsu

SVP, Business Development

Yi Hsiao

SVP, Process Development & Application

Liang Hong

SVP, Process Development & Application

Chaoyong Chen

SVP, Resource & Development

Xiaolian Huang

SVP, Purchasing

Pingzhong Huang, Ph.D.

SVP, Process Development

Yingwei Jiang

SVP, Human Resources

Yan Zhou, Ph.D.

VP, Quality Management

Xiangke Xu

VP, Finance

Yan Kuang

VP, EHS

Mark McLaws, Ph.D.

VP, CMC & Development

Scientific Advisory Board (SAB)

Asymchem has assembled a Scientific Advisory Board (SAB) of 10 distinguished academic and industrial scientists with expertise in areas including enzyme evolution, asymmetric catalysis, and green chemistry. The advisory board will provide advice on high-level strategic issues faced by Asymchem, and to assist in the identification of new business opportunities.

Advisory Board of Pharmaceutical Development Strategy

With the establishment of a pharmaceutical development strategy expert committee, Asymchem’s Board of Pharmaceutical Development Strategy aims to expand the company’s China market. By leveraging experts and scholars, we’ve been able to create a valuable intellectual synergy, actively promote Asymchem’s green pharmaceutical technology progress, and improve the professionalism and scientific level of strategic decisions.

Solutions, innovations, and know how delivered to your inbox. Sign up for our newsletter!